On‐demand treatment with Alverine (cas 150-59-4) citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study

Add time:09/30/2019    Source:infona.pl

BackgroundIn routine practice, irritable bowel syndrome (IBS) symptoms are often difficult to be relieved and impair significantly patients’ quality of life (QoL). A randomised, double‐blind, placebo‐controlled study has shown the efficacy of Alverine (cas 150-59-4) citrate/simeticone (ACS) combination for IBS symptom relief.AimAs IBS symptoms are often intermittent, this pragmatic study was designed to compare the efficacy of an on‐demand ACS treatment vs. that of usual treatments.MethodsRome III IBS patients were enrolled by 87 general practitioners who were randomly allocated to one of two therapeutic strategies: on‐demand ACS or usual treatment chosen by the physician. The primary outcome measure was the improvement of the IBSQoL score between inclusion and month 6.ResultsA total of 436 patients (mean age: 54.4 years; women: 73.4%) were included, 222 in the ACS arm and 214 patients in the usual treatment arm, which was mainly antispasmodics. At 6 months, improvement of IBSQoL was greater with ACS than with the usual treatment group (13.8 vs. 8.4; p < 0.0008). The IBS‐severity symptom score (IBS‐SSS) was lower with ACS than in the usual treatment arm with a mean (SE) decrease of 170.0 (6.6) vs. 110.7 (6.7), respectively (p = 0.0001). An IBS‐SSS < 75 was more frequent in the ACS group (37.7% vs. 16.0%; p < 0.0001). Improvement of both abdominal pain and bloating severity was also greater with the on‐demand ACS treatment, which was associated with both lower direct and indirect costs.ConclusionsAfter 6 months, on‐demand ACS treatment led to a greater improvement of QoL, reduced the burden of the disease and was more effective for IBS symptom relief than usual treatments.

We also recommend Trading Suppliers and Manufacturers of Alverine (cas 150-59-4). Pls Click Website Link as below: cas 150-59-4 suppliers

Prev:Clinical trial: the efficacy of Alverine (cas 150-59-4) citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome ‐ a randomized, double‐blind, placebo‐controlled study
Next:Effects of Dibenzyl disulfide (cas 150-60-7) on pressboard)